{"title":"68Ga PSMA PET/CT and 18F FDG PET/CT Findings in Osteonecrosis of the Jaw Induced by Denosumab.","authors":"Zehranur Tosunoğlu, Göksel Alçin, Elife Akgün, İlkay Gültürk, Esra Arslan","doi":"10.1097/RLU.0000000000005751","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer, prostate cancer, kidney cancer, multiple myeloma, osteoporosis, and the use of antiresorptive and antiangiogenic drugs are risk factors for osteonecrosis of the jaw (ONJ). Denosumab is a Receptor activator of nuclear factor kappa-Β ligand antagonist monoclonal antibody that inhibits the differentiation and function of osteoclasts over osteoblasts. It is an antiresorptive drug used to reduce the development of skeletal events in solid cancers. Denosumab-induced ONJ is a rare condition, occurring in 0% to 4.6% of cases. In this case, the findings of 68Ga prostate specific membrane antigen (PSMA) positron emission tomography (PET)/Computed Tomography (CT) and 18F Fluorodeoxyglucose (FDG) PET/CT are presented in a man with metastatic castration-resistant prostate cancer who developed ONJ due to denosumab use.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.6000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005751","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Breast cancer, prostate cancer, kidney cancer, multiple myeloma, osteoporosis, and the use of antiresorptive and antiangiogenic drugs are risk factors for osteonecrosis of the jaw (ONJ). Denosumab is a Receptor activator of nuclear factor kappa-Β ligand antagonist monoclonal antibody that inhibits the differentiation and function of osteoclasts over osteoblasts. It is an antiresorptive drug used to reduce the development of skeletal events in solid cancers. Denosumab-induced ONJ is a rare condition, occurring in 0% to 4.6% of cases. In this case, the findings of 68Ga prostate specific membrane antigen (PSMA) positron emission tomography (PET)/Computed Tomography (CT) and 18F Fluorodeoxyglucose (FDG) PET/CT are presented in a man with metastatic castration-resistant prostate cancer who developed ONJ due to denosumab use.
期刊介绍：
Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty.
Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
